7:55 am Chair’s Opening Remarks

  • Jack McLane Chief Scientific Officer, Catawba Research

Examining “Remittive” Therapy in Dermatology to Revolutionize the Dermatology Landscape

8:00 am Panel Discussion: Defining Remittive Therapy in Dermatology: Perspectives from Industry Experts

  • John Harris Professor & Chair Department of Dermatology, University of Massachusetts Medical School
  • Esther Garcia Gil Director, Global Clinical Development, Almirall
  • Subhashis Banerjee Vice-President, Disease Area Head, Rheumatology and Dermatology, Bristol Myers Squibb


  • What does remission actually look like in a dermatology context?
  • Is remittive therapy economically viable? How do youprice a drug that cures disease?
  • Does remission include an absence of psychological symptoms?

8:30 am Can we use Blood-Based Biomarkers in Dermatology to Aid Personalized Medicine and Drug Development?


  • Pathology associated collagen biomarkers for disease progression and pharmacodynamics in clinical research
  • Collagen mutations: measuring biomarkers associated with the mutations that cause skin diseases 

9:00 am Exploring the Translation of the Definition of Remission in Psoriasis to Atopic Dermatitis


  • Detailing aryl hydrocarbon receptor agonism biology and how it induces long standing therapeutic effects
  • Exploring the remittive effect in psoriasis – lessons from PSOARING
  • Atopic Dermatitis – potential translation of remittive effect & disease state differences

9:30 am Roundtable Discussion: What is Remission to you?


This interactive session gives you the opportunity to be part of the discussion, get ready to share ideas and learn from your peers. Amongst your tables talking points to consider include:

  • How do you define remittive?
  • Once defined, how we will measure if a therapy is truly remittive – will this be purely clinical or biological?
  • Will there be biological endpoints which allow proof of remission?
  • How close are we to applying remittive therapy, 5, 10 or 15 years?

10:00 am Session Reserved for Therapeutics Inc.



10:30 am Morning Break & Networking

Expanding the Dermatology Landscape With Innovative Treatment Regimes

Translational Track

11:00 am Combining Neuroscience & Immunology; Exploring the Neurocircuitry Behind Itch

  • Ferda Cevikbas Head of Translational Sciences, ASLAN Pharmaceuticals


  • Exploring cytokines related to itch to bridge the gap between neurology and immunology
  • Hearing about current candidates in development looking to harness this novel mechanism utilizing ex vivo human models of disease that are translatable to in vivo conditions

11:30 am First-in-Class: Evaluating the Efficacy & Safety of an Oral Selective Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor in Dermatologic & Other Conditions

  • Subhashis Banerjee Vice-President, Disease Area Head, Rheumatology and Dermatology, Bristol Myers Squibb


  • Exploring the mechanism of action of deucravacitinib and its impact on biomarkers and clinical outcomes in psoriasis and psoriatic arthritis
  • Delineating the distinct safety profile of deucravacitinib
  • Dermatology and beyond: exploring TYK2 inhibition in other chronic inflammatory disorders

12:00 pm Discovering & Optimizing Oral Peptides to Treat Systemic Inflammatory Diseases

  • Scott Plevy Executive Vice President & Therapeutic Head of Gastroenterology, Protagonist Therapeutics Inc.


  • Enhancing potency, specificity and selectivity, and metabolic stability of oral peptides to target inflammatory diseases
  • Navigating preclinical and phase I data to inform further development of oral peptides for dermatological disorders
  • Identifying the right patient population to engineer the next generation of oral therapies

12:30 pm Detailing Hedgehog-Signalling Inhibition as a Promising Target for Unmet Needs in the Dermatology Universe

  • Ofer Toledano Vice President of Research & Development, Sol Gel Technologies


  • Exploring the mechanism of Patidegib a hedgehog inhibitor (HHI) blocker, preventing new basal cell carcinomas in Gorlin Syndrome
  • Current data showcasing the potential of this mechanism and highlighting the benefits of topical HHIs over oral HHIs

Clinical Track

11:00 am Introducing CLE-400; Topical Alpha-2-Adrenergic Agonist as a First-in-Class Treatment for Localized Chronic Pruritus

  • Orna Goren Product Cluster Leader, Clexio Biosciences


  • Exploring activation of α2 adrenergic receptors on skin nociceptors in attenuating neural itch signaling
  • Detailing the effects of CLE-400 in preclinical pharmacological models
  • Presenting Notalgia Paresthetica as the first indication for CLE 400’s clinical development

11:30 am Developing the First-in-Class Topical “Soft” BET Inhibitor for the Treatment of Non-Segmental Vitiligo


  • Interrogating the role of the bromodomain and end terminal family of proteins and reviewing in vivo and ex vivo non-clinical efficacy of VYN201
  • Advancing the application of a soft drug and target tissue strategy to focus on-target effect and mitigate toxicity
  • Reviewing a Phase 1a/b study in healthy volunteers and patients with non-segmental vitiligo to inform future advances in using BET inhibitors

12:00 pm Exploring Transepidermal Delivery for Effective Drug Delivery Across the Skin


  • Explore why current drug delivery methods pose challenges to drug developers
  • Evaluate an innovative transepidermal delivery method for siRNA

12:30 pm Utilizing mTOR Inhibitors to Stabilize Intermediate Filaments in Epidermolysis Bullosa


  • Examining the role of mechanistic target of rapamycin (mTOR) in Epidermolysis Bullosa to unveil the rationale behind mTOR inhibition
  • Exploring mTOR inhibitor’s ability to degrade and remove mutant keratins through stimulation of autophagy
  • The promise of BM-3103 in orphan diseases as a novel approach to treating unmet needs

1:00 pm Lunch Break

2:00 pm From Scientific Insight to Clinical Results – the IL-17A & IL-17F Inhibiting Nanobody® Sonelokimab in Hidradenitis Suppurativa

  • Kristian Reich Chief Scientific Officer, MoonLake Immunotherapeutics AG


  • Unravelling the pathophysiology of HS lesions – evidence for a role of IL-17F in HS inflammatory lesions
  • Why penetration matters – new concepts around immune hotspots in inflammatory skin diseases
  • Translational validation – clinical data from a phase 2 study of the IL-17A and IL-17F inhibiting Nanobody® sonelokimab in HS

Redefining Reimbursement to Improve Investment & Fund Dermatological Development

2:30 pm Raising the Standards & Raising the Capital: Navigating a Dynamic Capital Market

  • Humberto Antunes Partner, Gore Range Capital & Former Chief Executive Officer, Galderma


  • What do investors look for in dermatological indications? How do you present a case for investment in a highly competitive market?
  • Navigating the commercial opportunity in rare dermatological diseases

3:00 pm Roundtable Discussion: Redefining Disease Burden of Skin Diseases to Improve Reimbursement


This interactive session gives you the opportunity to be part of the discussion, share ideas, and learn from your peers, get ready to be part of this conversation. Amongst your tables talking points to consider include:

  • Rethinking disease burden: demonstrating the value of novel drugs beyond clinical outcomes
  • Explore what healthcare insurers are looking for when reimbursing for topical vs. oral drugs
  • Share strategies in raising capital to fund clinical trials to better inform your capital decisions

3:30 pm Bridging Science and Economics: Leveraging Real-World Evidence for Payer Engagement in Dermatology

  • Janine Fournier Senior Director, Medical Value and Access, Dermavant Sciences


  • Exploring the significance of RWE in demonstrating the efficacy and safety
  • Discussing effective payer engagement strategies to demonstrate the value proposition of dermatological interventions through scientific evidence, including RWE
  • Highlighting the importance of bridging the gap between scientific research and economic considerations to inform payer decision-making and enhance access to innovative dermatological therapies.

4:00 pm Chairs Closing Remarks

  • Jack McLane Chief Scientific Officer, Catawba Research